retatrutide type 2 diabetes trial 2024 Phase III study demonstrates 30% weight loss Lilly's triple agonist, retatrutide, successful

This compound aligns with your Elite Bio Compounds Weight Management & Longevity research category

Editors note: This report has been updated to reflect findings from the TRIUMPH-1 clinical trial released on May 21, 2026 by Eli Lilly and Company.

Similarly, batch-specific impurity profiles and potency-verification data will be presented in ways that allow investigators to judge whether a newly procured lot is suitable for use mid-study or whether it should be reserved for future work to avoid confounding ongoing experiments

Social media interprets normal plateaus as medication failure because people post during frustrating plateau weeks, not during the subsequent weeks when weight loss resumes